Predictive factors for the development of brain metastases in patients with malignant melanoma: a study by the Anatolian society of medical oncology

被引：14

作者：

Gumusay, Ozge ^{[1
]}

Coskun, Ugur ^{[1
]}

Akman, Tulay ^{[2
]}

Ekinci, Ahmet Siyar ^{[3
]}

Kocar, Muharrem ^{[4
]}

Erceleb, Ozlem Balvan ^{[5
]}

Yazici, Ozan ^{[6
]}

Kaplan, Mehmet Ali ^{[7
]}

Berk, Veli ^{[8
]}

Cetin, Bulent ^{[1
]}

Taskoylu, Burcu Yapar ^{[9
]}

Yildiz, Ayhan ^{[10
]}

Goksel, Gamze ^{[11
]}

Alacacioglu, Ahmet ^{[12
]}

Demirci, Umut ^{[3
]}

Algin, Efnan ^{[1
]}

Uysal, Mukremin ^{[13
]}

Oztop, Ilhan ^{[14
]}

Oksuzoglu, Berna ^{[3
]}

Dane, Faysal ^{[4
]}

Gumus, Mahmut ^{[5
]}

Buyukberber, Suleyman ^{[1
]}

机构：

[1] Gazi Univ, Fac Med, Dept Internal Med, Div Med Oncol, TR-06500 Ankara, Turkey

[2] Balikesir State Hosp, Dept Internal Med, Div Med Oncol, Balikesir, Turkey

[3] Dr Abdurrahman Yurtaslan Training & Res Hosp, Dept Internal Med, Div Med Oncol, Ankara, Turkey

[4] Marmara Univ, Fac Med, Dept Internal Med, Div Med Oncol, Istanbul, Turkey

[5] Dr Lutfi Kirdar Kartal Training & Res Hosp, Dept Internal Med, Div Med Oncol, Istanbul, Turkey

[6] Ankara Numune Training & Res Hosp, Dept Internal Med, Div Med Oncol, Ankara, Turkey

[7] Dicle Univ, Fac Med, Dept Internal Med, Div Med Oncol, Diyarbakir, Turkey

[8] Erciyes Univ, Fac Med, Dept Internal Med, Div Med Oncol, Kayseri, Turkey

[9] Pamukkale Univ, Fac Med, Dept Internal Med, Div Med Oncol, Denizli, Turkey

[10] Inonu Univ, Fac Med, Dept Internal Med, Div Med Oncol, Malatya, Turkey

[11] Celal Bayar Univ, Fac Med, Dept Internal Med, Div Med Oncol, Manisa, Turkey

[12] Izmir Katip Celebi Univ Ataturk Training & Res Ho, Dept Internal Med, Div Med Oncol, Izmir, Turkey

[13] Afyon Kocatepe Univ, Fac Med, Dept Internal Med, Div Med Oncol, Afyon, Turkey

[14] Dokuz Eylul Univ, Fac Med, Dept Internal Med, Div Med Oncol, Izmir, Turkey

来源：

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY | 2014年 / 140卷 / 01期

关键词：

Melanoma; Brain metastases; Predictive factors; CENTRAL-NERVOUS-SYSTEM; CEREBRAL METASTASES; CUTANEOUS MELANOMA; PROGNOSTIC-FACTORS; THERAPY; SURVIVAL; LYMPHADENECTOMY; FEATURES; TRIAL; STAGE;

D O I：

10.1007/s00432-013-1553-7

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The development of brain metastases (BMs) was associated with poor prognosis in melanoma patients. Patients with BMs have a median survival of < 6 months. Melanoma is the third most common tumor to metastasize to the brain with a reported incidence of 10-40 %. Our aim was to identify factors predicting development of BMs and survival. We performed a retrospective analysis of 470 melanoma patients between 2000 and 2012. The logistic regression analyses were used to identify the clinicopathological features of primary melanoma that are predictive of BMs development and survival after a diagnosis of brain metastases. There were 52 patients (11.1 %) who developed melanoma BMs during the study period. The analysis of post-BMs with Kaplan-Meier curves has resulted in a median survival rate of 4.1 months (range 2.9-5.1 months). On logistic regression analysis site of the primary tumor on the head and neck (p = 0.002), primary tumor thickness (Breslow > 4 mm) (p = 0.008), ulceration (p = 0.007), and pathologically N2 and N3 diseases (p = 0.001) were found to be significantly associated with the development of BMs. In univariate analysis, tumor thickness and performance status had a significant influence on post-BMs survival. In multivariate analysis, these clinicopathologic factors were not remained as significant predictive factors. Our results revealed the importance of primary tumor characteristics associated with the development of BMs. Ulceration, primary tumor thickness, anatomic site, and pathologic a parts per thousand yenN2 disease were found to be significant predictors of BMs development.

引用

页码：151 / 157

页数：7

共 27 条

[1] The Benefits of Adjuvant. Radiation Therapy After Therapeutic Lymphadenectomy for Clinically Advanced, High-Risk, Lymph Node-Metastatic Melanoma [J].

Agrawal, Shefali ;

Kane, John M., III ;

Guadagnolo, Beverly A. ;

Kraybill, William G. ;

Ballo, Matthew T. .

CANCER, 2009, 115 (24) :5836-5844

[2]

AMER MH, 1978, CANCER-AM CANCER SOC, V42, P660, DOI 10.1002/1097-0142(197808)42:2<660::AID-CNCR2820420237>3.0.CO

[3]

2-E

[4] MULTIFACTORIAL ANALYSIS OF MELANOMA - PROGNOSTIC HISTOPATHOLOGICAL FEATURES COMPARING CLARKS AND BRESLOWS STAGING METHODS [J].

BALCH, CM ;

MURAD, TM ;

SOONG, SJ ;

INGALLS, AL ;

HALPERN, NB ;

MADDOX, WA .

ANNALS OF SURGERY, 1978, 188 (06) :732-742

[5] Combined-modality therapy for patients with regional nodal metastases from melanoma [J].

Ballo, MT ;

Ross, MI ;

Cormier, JN ;

Myers, JN ;

Lee, JE ;

Gershenwald, JE ;

Hwu, P ;

Zagars, GK .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 64 (01) :106-113

[6] CENTRAL NERVOUS-SYSTEM METASTASES IN MALIGNANT-MELANOMA [J].

BULLARD, DE ;

COX, EB ;

SEIGLER, HF .

NEUROSURGERY, 1981, 8 (01) :26-30

[7]

CASSEL WA, 1986, CANCER-AM CANCER SOC, V57, P1302, DOI 10.1002/1097-0142(19860401)57:7<1302::AID-CNCR2820570709>3.0.CO

[8]

2-Z

[9] Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma:: final results of EORTC 18991, a randomised phase III trial [J].

Eggermont, Alexander M. M. ;

Suciu, Stefan ;

Santinami, Mario ;

Testori, Alessandro ;

Kruit, Wim H. J. ;

Marsden, Jeremy ;

Punt, Cornelis J. A. ;

Sales, Francois ;

Gore, Martin ;

MacKie, Rona ;

Kusic, Zvonko ;

Dummer, Reinhard ;

Hauschild, Axel ;

Musat, Elena ;

Spatz, Alain ;

Keilholz, Ulrich .

LANCET, 2008, 372 (9633) :117-126

[10] Ulceration and stage are predictive of interferon efficacy in melanoma: Results of the phase III adjuvant trials EORTC 18952 and EORTC 18991 [J].

Eggermont, Alexander M. M. ;

Suciu, Stefan ;

Testori, Alessandro ;

Kruit, Wim H. ;

Marsden, Jeremy ;

Punt, Cornelis J. ;

Santinami, Mario ;

Sales, Francois ;

Schadendorf, Dirk ;

Patel, Poulam ;

Dummer, Reinhard ;

Robert, Caroline ;

Keilholz, Ulrich ;

Yver, Antoine ;

Spatz, Alan .

EUROPEAN JOURNAL OF CANCER, 2012, 48 (02) :218-225

← 1 2 3 →